All
Identifying Rare Biomarker Could Help a Subset of Patients With Lung Cancer
August 31st 2017RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.
Bosulif Granted Priority Review in CML
August 30th 2017Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
Gazyva Granted Priority Review for Follicular Lymphoma
August 29th 2017The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.
FDA Approves Frontline Faslodex for Breast Cancer Subset
August 28th 2017The Food and Drug Administration (FDA) approved Faslodex (fulvestrant) to treat patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in postmenopausal women who were not treated with endocrine therapy.
End-of-Life Care Is Suboptimal in Elderly Patients With AML
August 25th 2017End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.